Altimmune
$5.55
293
-$0.05-0.89% Monday 21:00
Statistics
Day High
5.75
Day Low
5.26
52W High
7.73
52W Low
2.9
Volume
5,164,235
Avg. Volume
4,911,059
Mkt Cap
578.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Jan 17
$87.3
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
26MarExpected
Expected EPS
-0.234
Actual EPS
N/A
Financials
-475,295%Profit Margin
Unprofitable40,000Revenue
-190.12MNet Income
Analyst Ratings
$16.67Average Price Target
The highest estimate is 24.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 33%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.36B
Moderna
MRNA
Mkt Cap10.61B
BioNTech
BNTX
Mkt Cap24.99B
Pfizer
PFE
Mkt Cap140.15B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Inovio Pharmaceuticals
INO
Mkt Cap124.89M
Dynavax Technologies
DVAX
Mkt Cap1.2B
GSK
GSK
Mkt Cap94.51B
Sanofi
SNY
Mkt Cap124.45B
About
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Dr. Vipin K. Garg Ph.D.
Employees
59
Country
US
ISIN
US02155H2004
Listings
0 Comments
Share your thoughts
FAQ
What is Altimmune stock price today?▼
The current price of ALT is $5.55 USD — it has decreased by -0.89% in the past 24 hours. Watch Altimmune stock price performance more closely on the chart.
What is Altimmune stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Altimmune stocks are traded under the ticker ALT.
Is Altimmune stock price growing?▼
ALT stock has fallen by -10.19% compared to the previous week, the month change is a +58.12% rise, over the last year Altimmune has showed a -13.82% decrease.
What is Altimmune market cap?▼
Today Altimmune has the market capitalization of 578.61M
When is the next Altimmune earnings date?▼
Altimmune is going to release the next earnings report on March 26, 2026.
What were Altimmune earnings last quarter?▼
ALT earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.27 USD resulting in a +22.83% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Altimmune revenue for the last year?▼
Altimmune revenue for the last year amounts to 40,000 USD.
What is Altimmune net income for the last year?▼
ALT net income for the last year is -190.12M USD.
Does Altimmune pay dividends?▼
Yes, ALT dividends are paid en. The last dividend per share was 87.3 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Altimmune have?▼
As of February 03, 2026, the company has 59 employees.
In which sector is Altimmune located?▼
Altimmune operates in the Health Care sector.
When did Altimmune complete a stock split?▼
The last stock split for Altimmune was on September 14, 2018 with a ratio of 1:30.
Where is Altimmune headquartered?▼
Altimmune is headquartered in Gaithersburg, US.